 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /flɛˈkeɪnaɪd/ flek-AY-nyde |
| Trade names | Tambocor, others |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a608040 |
|
Pregnancy category |
|
| Drug class | Ic antiarrhythmic [1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 40% |
| Metabolism | CYP2D6 (limited) |
| Elimination half-life | 20 hours (range 12–27 hours) |
| Excretion | Kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C17H20F6N2O3 |
| Molar mass | 414.348 g·mol−1 |
| 3D model ( JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 
(what is this?)
(verify) | |
Flecainide is a medication used to prevent and treat abnormally fast heart rates. [1] This includes ventricular and supraventricular tachycardias. [1] Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments. [1] Its use does not decrease a person's risk of death. [1] It is taken by mouth or injection into a vein. [1] [3]
Common side effects include dizziness, problems seeing, shortness of breath, chest pain, and tiredness. [1] Serious side effects may include cardiac arrest, arrhythmias, and heart failure. [1] It may be used in pregnancy, but has not been well studied in this population. [3] [4] Use is not recommended in those with structural heart disease or ischemic heart disease. [1] Flecainide is a class Ic antiarrhythmic agent. [1] It works by decreasing the entry of sodium in heart cells, causing prolongation of the cardiac action potential. [1]
Flecainide was approved for medical use in the United States in 1985. [1] It is available as a generic medication. [3] A month supply in the United Kingdom costs the NHS about £7.68 as of 2019. [3] In the United States the wholesale cost of this amount is about 18.60 USD. [5] In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions. [6] [7]
References
- ^ a b c d e f g h i j k l "Flecainide Acetate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 28 August 2021. Retrieved 7 April 2019.
-
^ Cite error: The named reference
WHO2020DDDwas invoked but never defined (see the help page). - ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 103. ISBN 9780857113382.
- ^ "Flecainide (Tambocor) Use During Pregnancy". Drugs.com. Archived from the original on 28 August 2021. Retrieved 7 April 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Flecainide Acetate - Drug Usage Statistics". ClinCalc. Archived from the original on 28 August 2021. Retrieved 11 April 2020.
|
| |
|
| |
| Clinical data | |
|---|---|
| Pronunciation | /flɛˈkeɪnaɪd/ flek-AY-nyde |
| Trade names | Tambocor, others |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a608040 |
|
Pregnancy category |
|
| Drug class | Ic antiarrhythmic [1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 40% |
| Metabolism | CYP2D6 (limited) |
| Elimination half-life | 20 hours (range 12–27 hours) |
| Excretion | Kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C17H20F6N2O3 |
| Molar mass | 414.348 g·mol−1 |
| 3D model ( JSmol) | |
| Chirality | Racemic mixture |
| |
| |
|
(what is this?)
(verify) | |
Flecainide is a medication used to prevent and treat abnormally fast heart rates. [1] This includes ventricular and supraventricular tachycardias. [1] Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments. [1] Its use does not decrease a person's risk of death. [1] It is taken by mouth or injection into a vein. [1] [3]
Common side effects include dizziness, problems seeing, shortness of breath, chest pain, and tiredness. [1] Serious side effects may include cardiac arrest, arrhythmias, and heart failure. [1] It may be used in pregnancy, but has not been well studied in this population. [3] [4] Use is not recommended in those with structural heart disease or ischemic heart disease. [1] Flecainide is a class Ic antiarrhythmic agent. [1] It works by decreasing the entry of sodium in heart cells, causing prolongation of the cardiac action potential. [1]
Flecainide was approved for medical use in the United States in 1985. [1] It is available as a generic medication. [3] A month supply in the United Kingdom costs the NHS about £7.68 as of 2019. [3] In the United States the wholesale cost of this amount is about 18.60 USD. [5] In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions. [6] [7]
References
- ^ a b c d e f g h i j k l "Flecainide Acetate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 28 August 2021. Retrieved 7 April 2019.
-
^ Cite error: The named reference
WHO2020DDDwas invoked but never defined (see the help page). - ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 103. ISBN 9780857113382.
- ^ "Flecainide (Tambocor) Use During Pregnancy". Drugs.com. Archived from the original on 28 August 2021. Retrieved 7 April 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
- ^ "Flecainide Acetate - Drug Usage Statistics". ClinCalc. Archived from the original on 28 August 2021. Retrieved 11 April 2020.